Long-term migraine prevention with topiramate: Open-label extension of pivotal trials

Headache

Volumn 46, Issue 7, 2006, Pages 1151-1160

  Rapoport, Alan ^a   Mauskop, Alexander ^b   Diener, Hans Christoph ^c   Schwalen, Susanne ^d   Pfeil, Joop ^e  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b New York Headache Center   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Jausseu Cilag EMEA   (Netherlands)

^e Estimate Medical Statistics BV   (Netherlands)

Author keywords

Headache; Migraine prevention; Topiramate

Indexed keywords

PLACEBO; TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BONE DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MIGRAINE; MIGRAINE AURA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; SINUSITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745585085     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00506.x     Document Type: Article

References (21)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Results from the American Migraine Study II. Headache. 2001;41:646-657.
2. Lipton RB, Liberman LN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003;23:441-450.
3. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001;41:638-645.
4. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999;159:813-818.
5. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59:1011-1024.
6. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. Available at: www.aan.com/professionals/practice/pdfs/gl0090.pdf. Accessed October 7, 2005.
7. Snow V, Weiss K, Wall EM, Mottur-Pilson C, for the American Academy of Physicians and the American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute migraine attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840-849.
8. Lipton RB, et al. Migraine prevention patterns in a community sample: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2005;45:792.
9. Silberstein SD, Neto W, Schmitt J, Jacobs D, for the MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neural. 2004;61:490-495.
10. Brandes JL, Saper JR, Diamond M, et al, for the MIGR-002 Study Group. Topiramate for migraine prevention. A randomized controlled trial. JAMA. 2004;291:965-973.
11. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943-950.
12. Forde G, Lake A, Jacobs D, et al. The efficacy of topiramate in migraine prevention: Analyses of pooled data from two, 26-week, placebo-controlled, double-blind topiramate trials. Presented at the 2004 Annual Meeting of the American Headache Society, Vancouver, British Columbia, Canada. Poster S171.
13. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(suppl 1):S17-S20.
14. Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res. 2003;55:225-233.
15. Zona C, Ciotto MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997;231:123-126.
16. Shank RP, Doose DR, Streeter AJ, Bialer M. Plasma and whole blood pharmacokinetics of topiramate: The role of carbonic anhydrase. Epilepsy Res. 2005;63:103-112.
17. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(suppl 1):S52-S60.
18. Freitag F, Láinez MJA, Neto W, Shi Y. Comparing the incidence of adverse events in the titration and maintenance phases of placebo-controlled trials of topiramate for migraine prevention. Headache. 2005;45:821-822.
19. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(2):CD003225. Review.
20. Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia. 1996;16:328-336.
21. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia. 2004;24(suppl 1):9-160.